Results
Title

The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.

Authors

Kuwabara, Yoshihiro; Yasuno, Shinji; Kasahara, Masato; Ueshima, Kenji; Nakao, Kazuwa

Abstract

Background: The influence of uric acid (UA) on renal function and the significance of UA-lowering therapy are unclear. The purpose of the sub-analysis of the Assessment of Clinical Usefulness in chronic kidney disease patients with Atorvastatin (ASUCA) trial was to evaluate the influence of serum UA levels on renal function in Japanese chronic kidney disease patients with hyperlipidemia. Methods: Of 344 participants in the ASUCA trial, 279 participants whose UA levels at both baseline and 24 months were available were included. Based on UA level at baseline or mean UA level during the trial period, they were divided into four groups: 2, respectively. A negative correlation between changes in eGFR after 24 months and baseline UA level was observed with adjustment for confounding factors. The relationship between changes in eGFR and mean UA levels during trial period showed a similar trend. Conclusion: In CKD patients with dyslipidemia, hyperuricemia was an independent risk factor for CKD progression. An ongoing clinical trial (TARGET-UA, UMIN-ID 000,026,741) may reveal the significance of strict UA-lowering therapy in CKD patients.

Subjects

URIC acid; CHRONIC kidney failure; CHRONICALLY ill; GLOMERULAR filtration rate; DYSLIPIDEMIA

Publication

Clinical & Experimental Nephrology, 2020, Vol 24, Issue 5, p420

ISSN

1342-1751

Publication type

Academic Journal

DOI

10.1007/s10157-019-01840-4